Loading…
← CockpitCompetitor Analysis › 600535.SS Tasly Pharmaceutical Group Co. Ltd. Class AOpen in the cockpit ↗

Tasly Pharmaceutical Group Co. Ltd. Class A600535.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese TCM pharma company known for Compound Danshen Dripping Pills, a cardiovascular traditional-medicine product it has tried to get FDA-approved.

Momentum leader 86
Mkt cap
$3.19B
US dollars, full cap
Free float
47%
of shares outstanding
$/day
$27.5M
20-day average traded
Fwd P/E
16.7×
forward earnings
ROIC−WACC
+8.9 pp
WACC 5.4%
Hurdle
+2 pp
Req g minus delivered
Next earnings
132 days
30 Mar 2027
Close · CNYCN¥14.36
1D+0.2%
1W+2.7%
1M+1.8%
3M-6.9%
6M-1.9%
YTD-4.7%
1Y-5.4%
ATR %2.1%
52w lowhigh11.6% off high

What Tasly Pharmaceutical does

Chinese TCM pharma company known for Compound Danshen Dripping Pills, a cardiovascular traditional-medicine product it has tried to get FDA-approved.

Most income comes from one product family, sold mainly through hospitals, so inclusion on China's state insurance reimbursement list and the price it fetches matter a great deal. A Tianjin-based group, Tasly's parent, is the controlling shareholder.

Products and services

  • Compound Danshen Dripping Pills
  • Other TCM/generic products

Customers

  • Hospitals/pharmacies
  • Patients with cardiovascular conditions

Where it sits in the supply chain

  • Health Care
  • Traditional Chinese medicine
  • TCM cardiovascular products

What could go right

  • Cardiovascular TCM demand; potential Western market entry

What could go wrong

  • TCM efficacy/regulatory scrutiny
  • Centralized procurement price pressure

Moat: narrow (brand, IP / patents). Long-standing branded TCM formula with clinical data supporting cardiovascular use.

Headquarters: Tianjin, China · Employees: 10,563

Named competitors

Tasly Pharmaceutical at a glance

Size Tasly Pharmaceutical (600535.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.19B, the 757th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.36 on 18 Nov 2026.

Performance Over six months the shares fell 1.9%, against +1.3% for the median peer and -20.0% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.

Growth Revenue fell 4.2% over the last twelve months (peer median +25.3%); the operating margin is 18.9% (peer median 11.1%).

Valuation It trades at 16.7× forward earnings against a peer median of 22.1× (4th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is -10%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 8.9 points above its cost of capital (5.4% WACC).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

10011021 May 202621 Aug 202618 Nov 2026Peer median 104600535.SS 100
Six months, rebased to 100: Tasly Pharmaceutical against the median of its 20 peers (local-currency closes).

Tasly Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥8.00BCN¥8.15BCN¥8.42BCN¥8.59BCN¥8.55B
Revenue growth—-3%-2%+1%—
Gross profitCN¥5.67BCN¥5.25BCN¥5.44BCN¥5.53BCN¥5.26B
EBITDAn/aCN¥1.82BCN¥1.93BCN¥1.96BCN¥1.79B
Net incomeCN¥1.22BCN¥1.10BCN¥956MCN¥1.07B-CN¥264M
Free cash flowCN¥1.70BCN¥1.09BCN¥1.49BCN¥1.94BCN¥1.93B
Capital expenditureCN¥350MCN¥381MCN¥565MCN¥669MCN¥404M
Total debtCN¥284MCN¥1.48BCN¥1.85BCN¥2.96BCN¥2.47B

Quarterly statements and history in the cockpit →

Tasly Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%0%+20%688266LEGN600511ACAD2696VKTX000739VCEL002773PPLPHARMA2096VRDNAMLX0867NEULANDLAB002262688180ARQTACUTAASSFZN600535.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Tasly Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×688266LEGN600511ACAD2696000739VCELPPLPHARMA2096NEULANDLABARQTACUTAAS600535.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tasly Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%688266600511ACAD2696000739VCELARQT600535.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Tasly Pharmaceutical is the large dot.

Tasly Pharmaceutical competitors and peer comparison

Head to head with its named competitors (600535.SS vs 600085.SS vs 000538.SZ vs 002603.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Tasly Pharmaceutical 600535.SS$3.19B-2%-4%19%16.7×-7.5%
Beijing TongRenTang 600085.SS$4.91B-12%-17%8%28.7×1.7%
Yunnan Baiyao 000538.SZ$15.0B+11%+5%11%18.3×-0.2%
Shijiazhuang Yiling Pharmaceutical 002603.SZ$3.83B-7%+32%21%17.5×-3.9%
Shandong Buchang Pharmaceuticals 603858.SS$2.25B-7%+4%10%n/a-2.5%
Jiangsu Kanion Pharmaceutical 600557.SS$989M-9%+8%7%19.8×2.3%

How Tasly Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tasly Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure600535.SSPeer medianRank in peer set
1-month return+1.8%-5.0%9th highest of 21
6-month return-1.9%+1.3%10th lowest of 21
Distance from 52-week high-11.6%-29.6%7th highest of 21
Revenue growth (TTM)-4.2%+25.3%4th lowest of 20
Operating margin18.9%11.1%6th highest of 19
Forward P/E16.7×22.1×4th cheapest of 17
Growth the price implies (Req g, 7 yrs)-7.5%4.7%2nd least demanding of 12
Growth delivered (Del g)-9.6%+12.0%lowest of 12
Hurdle (Req g minus delivered)+2.1 pp-14.0 pp2nd most demanding of 12
ROIC minus cost of capital+8.9 pp+5.7 pp8th highest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Tasly Pharmaceutical 600535.SSChina$3.19B-2%-4%19%16.7×-7.5%-9.6%
Suzhou Zelgen Biopharmaceuticals 688266.SSChina$3.13B-25%+136%29%36.1×17.7%+98.4%
Legend Biotech Corp. Sponsored ADR LEGNUnited States$3.12B-42%+50%3%34.2×n/an/a
China National Medicines 600511.SSChina$3.26B+3%+3%4%10.5×-10.0%+5.4%
ACADIA Pharmaceuticals ACADUnited States$3.08B-15%+15%10%17.8×9.2%+19.4%
Shanghai Henlius Biotech 2696.HKHong Kong$3.05B-39%+33%12%21.3×14.1%+61.4%
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%22.9×4.7%+4.5%
Vericel VCELUnited States$2.99B+66%+25%8%68.3×46.5%+17.3%
Chengdu Kanghong Pharmaceutical 002773.SZChina$2.99B-1%-11%24%20.1×-3.3%+7.0%
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%150.8×n/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%13.5×-3.4%+10.6%
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%n/an/an/a
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
China Medical System 0867.HKHong Kong$2.95B-15%+15%20%9.8×1.1%+2.7%
Neuland Laboratories NEULANDLAB.NSIndia$2.95B+28%+50%26%63.4×n/an/a
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%19.6×-2.1%+12.0%
Shanghai Junshi Biosciences 688180.SSChina$3.48B-31%+29%-15%n/an/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%41.0×49.2%+367.3%
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%63.6×n/an/a
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%16.8×n/an/a

Questions

Who are Tasly Pharmaceutical's main competitors?
Named competitors: Beijing TongRenTang (600085.SS), Yunnan Baiyao Group (000538.SZ), Shijiazhuang Yiling Pharmaceutical (002603.SZ), Shandong Buchang Pharmaceuticals (603858.SS), Jiangsu Kanion Pharmaceutical (600557.SS). The cockpit's measured peer set (industry) also includes Suzhou Zelgen Biopharmaceuticals (688266.SS), Legend Biotech Corp. Sponsored ADR (LEGN), China National Medicines (600511.SS), ACADIA Pharmaceuticals (ACAD), Shanghai Henlius Biotech (2696.HK), Viking Therapeutics (VKTX).
Is Tasly Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 16.7× against a peer median of 22.1×, 4th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is -10%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Tasly Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -1.9% against +1.3% for the median peer; over one year -5.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.